0
Diffuse Lung Disease: Evaluation and Treatment of ILD |

The Efficacy of Pirfenidone in the Treatment of Idiopathic Pulmonary Fibrosis: A Single-Institution Retrospective Study in Japan

Kai Yazaki, MD; Yukiko Miura, MD; Manato Taguchi, MD; Shunichi Nishima, MD; Norihito Hida, MD; Kazufumi Yoshida, MD; Kentaro Hyodo, MD; Jun Kanazawa, MD; Kenji Nemoto, MD; Takio Takaku, MD; Shuji Oishi, MD; Kenji Hayashihara, MD; Takefumi Saito, MD
Author and Funding Information

NHO Ibarakihigashi National Hospital, Naka-gun, Japan


Copyright 2016, American College of Chest Physicians. All Rights Reserved.


Chest. 2016;150(4_S):483A. doi:10.1016/j.chest.2016.08.497
Text Size: A A A
Published online

Extract

SESSION TITLE: Evaluation and Treatment of ILD

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Wednesday, October 26, 2016 at 01:30 PM - 02:30 PM

PURPOSE: Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease. The 2011 ATS/ERS/JRS/ALAT guideline did not recommend drug therapy, but Pirfenidone and Nintedanib became “conditional recommendation for use” on the 2015 guideline because these were proved to reduce disease progression in patients with IPF. To assess the other efficacy of Pirfenidone, we examined Japanese patients with IPF.

First Page Preview

View Large
First page PDF preview

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543